Business Context and Reporting Period
This Form 8-K Current Report was filed by MacroGenics, Inc. (MGNX) on January 5, 2023, covering events occurring on January 3 and January 4, 2023. The filing primarily addresses corporate governance changes involving the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance.
Material Changes
- Board Appointment: The Board appointed Meenu Chhabra Karson as a director, effective January 3, 2023.
- Committee Assignment: Ms. Chhabra Karson was appointed to the Audit Committee effective immediately.
- Director Class: She is designated as a Class III director, serving until the 2025 Annual Meeting of Stockholders.
Compensatory Arrangements and Outlook
- Compensation: Ms. Chhabra Karson will receive an annual retainer consistent with the Company's Director Compensation Program.
- Equity Grant: Upon appointment, she was granted an option to purchase 36,000 shares of common stock at the closing market price on the Effective Date.
- Vesting Schedule: The options vest in 36 substantially equal monthly portions beginning on the first monthly anniversary of the grant date, contingent on continued service.
- Related Disclosure: A press release dated January 4, 2023, also announced the appointment of Dr. Margaret A. Liu to the Board.
Investor Verification Checklist
- Verify the closing market price of MGNX common stock on January 3, 2023, to determine the exercise price of the 36,000 share option grant.
- Review the Company's most recent definitive proxy statement (filed April 8, 2022) for details on the annual retainer amount for non-employee directors.
- Confirm the qualifications and background of the new directors (Ms. Chhabra Karson and Dr. Liu) as detailed in the referenced press release.